Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 13, 2021

MGC Pharma starts enrolment in Phase III Covid-19 trial of CimetrA

The data from the Phase III trial is anticipated to allow future trials of the therapeutic for treating Covid-19 patients.

Phytocannabinoid-derived therapies developer MGC Pharmaceuticals has started participant enrolment in Phase III clinical trial of CimetrA to treat patients hospitalised with Covid-19.

The trial, which is assessing the efficacy and safety of the therapeutic, recruited the first participants at the Rambam Medical Center in Israel.

CimetrA encapsulates Graft Polymer’s GraftBio self nano-emulsifying drug delivery system (SNEDDS), which carries active ingredients in high concentrations to the cells.

It is intended to address the pathophysiological effects of Covid-19.

The IMP production and validation of the therapeutic have been completed. In addition, the company secured ethics committee approval in March 2021 to conduct the Phase III trial.

For the trial, 252 patients with moderate Covid-19 will be enrolled, with 28 days for each subject.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The natural formulation of CimetrA containing curcumin and Boswellia serrata, which have anti-inflammatory properties, will be tested. GraftBio is expected to deliver these natural ingredients more efficiently at higher concentrations.

Following the trial initiation, MGC Pharma will finish the necessary clinical data to meet the requirements set by the European Medicines Agency (EMA).

The company also intends to submit more pre-clinical and dose-finding data to meet all EMA qualifications with the Phase III trial results.

Apart from validating claims related to the therapeutic, the Phase III results are expected to enable future trials and commercial discussions currently being carried out for potential distribution and sale agreements in the near term.

MGC Pharma co-founder and managing director Roby Zomer said: “The commencement of the Phase III clinical trial is a milestone achievement for both MGC Pharma and the medicinal cannabis industry.

“Testing CimetrA as an IMP will have great implications for those suffering with Covid-19 and ensure the risk of healthcare systems becoming overwhelmed is minimised.”

In May 2020, the company started a Phase II trial of ArtemiC for patients suffering from Covid-19.

 

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU